A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Orteronel (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacodynamics
- 20 Sep 2017 Status changed from active, no longer recruiting to completed.
- 19 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
- 25 Apr 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2016.